



張安德中醫藥國際貢獻獎
CHEUNG ON TAK
INTERNATIONAL AWARD
FOR OUTSTANDING CONTRIBUTION
TO CHINESE MEDICINE

**The 7th Cheung On Tak International Award for
Outstanding Contribution to Chinese Medicine
Award Ceremony-cum-Award Lectures**

**第七屆張安德中醫藥國際貢獻獎
頒獎典禮暨得獎學人講座**

Wednesday | 27 March 2024 | 15:00 - 17:30 (HKT)

Mr. and Mrs. Lau Chor Tak Multi-Purpose Hall
Level 2, Madam Kwok Chung Bo Fun Sports and Cultural Centre,
Shaw Campus, Hong Kong Baptist University
香港浸會大學逸夫校園 郭鍾寶芬女士康體文娛中心二樓 劉佐德伉儷多用途會堂

 香港浸會大學
HONG KONG BAPTIST UNIVERSITY

School of 
Chinese Medicine

Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine 張安德中醫藥國際貢獻獎

With its rapid development in different parts of the world, traditional Chinese medicine is playing an increasingly important role in the healthcare systems in many countries. Against this backdrop, the School of Chinese Medicine of the Hong Kong Baptist University established the International Award for Outstanding Contribution to Chinese Medicine in 2011. The objectives of the Award are to honour scientists and scholars who have made groundbreaking and internationally recognised achievements in advancing the internationalisation of Chinese medicine or Chinese medicine research, and to promote the modernisation and internationalisation of Chinese medicine for the benefit of the global community.

Established by a generous donation from the Cheung On Tak Charity Foundation, the Award is named after the Foundation's Founder, Mr. Cheung On Tak. The Cheung On Tak International Award is conferred biennially on one or two scholars, with a total monetary prize of HK\$500,000.

傳統中醫藥在世界各地急促發展，在許多國家的醫療保健制度中的角色日趨重要。因此，香港浸會大學中醫藥學院於 2011 年設立中醫藥國際貢獻獎，目的是表揚在推動中醫藥國際化、或在中醫藥研究領域，取得具突破性、及獲國際認可成就的科學家和學者，並促進中醫藥現代化和國際化，以及推動中醫藥發展，惠澤全球。

承蒙張安德慈善基金的慷慨捐資，此獎項得以設立，並以其基金創辦人張安德院士的名字命名，以彰善舉。張安德中醫藥國際貢獻獎每兩年頒發一次，每屆授予一至兩位學者，獎金總額為港幣五十萬元。

Cheung On Tak Charity Foundation

張安德慈善基金



The Cheung On Tak Charity Foundation was founded by renowned industrialist Mr. Cheung On Tak in 1992 to support society and the needy through facilitating the development of education, religious and medical services. Formerly consultant of Man Po Investment Company Limited and On Tak Enterprise Company Limited, Mr. Cheung is well-known for his philanthropy and commitment to serving the society. He has held numerous positions in trade,

industrial, and community organizations, such as President and Chairman of Chiu Chau Plastic Manufacturers Association Company Limited, Director of the Hong Kong Chiu Chow Chamber of Commerce, Honorary President of The Aberdeen Kai-fong Welfare Association Social Service Centre, Chairman of the Southern District Anti-drug Campaign and President of the Hong Kong Cheung Shi Clansmen's Association. In 2011, Mr. Cheung was conferred Honorary University Fellowship by the Hong Kong Baptist University.

Over the years, the Foundation has contributed generously to education and research initiatives and has made substantial donations to various Hong Kong universities supporting their advancement.

張安德慈善基金由張安德院士於 1992 年創辦，旨在促進教育、宗教及醫療服務的發展，扶危解困，回饋社會，造福社群。張先生是著名工業家，曾任萬寶置業有限公司及安德企業有限公司顧問，一向熱心公益和履行社會責任。他曾在許多工商及社區團體擔任職務，包括潮僑塑膠廠商會會長和主席、香港潮州商會會董、香港仔街坊福利會社會服務中心榮譽會長、南區反吸毒運動委員會主席、香港張氏宗親會會長等。2011 年，張先生獲香港浸會大學頒授榮譽大學院士榮銜。

張安德慈善基金自成立以來熱心支持本港的教育事業，曾先後捐資多間大學，積極推動本地高等教育的發展。

Panel of Adjudicators of the 7th Award 第七屆評審委員會

Chairman

Professor CHEN Kaixian

- Academician, Chinese Academy of Sciences
- Principal Investigator and Former Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Tenured Professor, Director of Academic Committee and Former President, Shanghai University of Traditional Chinese Medicine



主席

陳凱先院士

- 中國科學院院士
- 中國科學院上海藥物研究所研究員、前任所長
- 上海中醫藥大學終身教授、學術委員會主任、前任校長

Members

Professor CHEN Keji

- Academician, Chinese Academy of Sciences
- Award Winner of the First Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine



成員

陳可冀院士

- 中國科學院院士
- 第一屆「張安德中醫藥國際貢獻獎」得獎人

Professor LEUNG Ping-Chung SBS, OBE, JP

- Director, Centre for Clinical Trials on Chinese Medicine, Institute of Chinese Medicine, The Chinese University of Hong Kong
- Director, State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants in The Chinese University of Hong Kong



梁秉中教授 SBS, OBE, JP

- 香港中文大學中醫中藥研究所臨床研究中心總監
- 藥用植物應用研究國家重點實驗室（香港中文大學）主任

Professor JIA Wei

- The then Acting Dean of Chinese Medicine and Cheung On Tak Endowed Professor in Chinese Medicine, Hong Kong Baptist University



賈偉教授

- 時任香港浸會大學中醫藥學院署理院長、張安德中醫藥教授

Professor SO Kwok-Fai

- Academician, Chinese Academy of Sciences
- Professor Emeritus, The University of Hong Kong



蘇國輝院士

- 中國科學院院士
- 香港大學榮休教授

Alexander Ping-Kong WAI

- President and Vice-Chancellor, Hong Kong Baptist University



衛炳江教授

- 香港浸會大學校長

Dr. Kennedy WONG Ying-Ho BBS, LLD, DCL, JP

- Managing Partner, Philip K. H. Wong, Kennedy Y. H. Wong & Co.
- Chairman, Advisory Committee of School of Chinese Medicine, Hong Kong Baptist University



黃英豪博士

BBS, LLD, DCL, JP

- 黃乾亨黃英豪律師事務所首席合夥人
- 香港浸會大學中醫藥學院諮詢委員會主席

Professor Kenneth WU Kun-Yu

- Academician, Academia Sinica
- President Emeritus, Honorary Investigator, National Health Research Institutes, Taiwan



伍焜玉院士

- 中央研究院院士
- 台灣國家衛生研究院前院長、榮譽研究員

(In alphabetical order by last name 按英文姓氏字母排序)

Proceedings 程序

Award Ceremony 頒獎典禮



Opening Address 開幕辭

Professor Alexander Ping-kong Wai
President and Vice-Chancellor
校長 衛炳江教授

Presentation Speech 介紹得獎學人

Professor Chen Kaixian, Chairman, Panel of Adjudicators
評審委員會主席 陳凱先院士

Presentation of Awards 頒發獎項

Mr Gavin Cheung & Ms Annie Cheung
Directors, Cheung On Tak Charity Foundation
張安德慈善基金董事 張敬智先生、張敬慧女士

Mr Paul WY Poon, MH, Deputy Chairman, Council and Court
校董會暨諮議會副主席 潘偉賢先生, MH

Award Winners' Addresses 得獎學人致辭

Presentation of Mementos 致送紀念品

Award Lectures 得獎學人講座



Original Studies on the Diagnosis and Treatment of Rheumatic Diseases by Integrating Chinese and Western Medicine 中西醫結合診療風濕病的原創性研究

Academician Liu Liang
劉良院士

Internationalisation of TCM: A Unique Way of Mutual Learning Between Eastern and Western Civilisations 中醫國際化：東西方文明互鑒的獨特之道

Professor Xu Anlong
徐安龍教授

Dialogue with Award Winners 與得獎學人對話



AWARD WINNERS' ADDRESSES

得獎學人感言

“ I am deeply honored to receive the Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine. This prestigious award is not only a recognition of my efforts in researching and developing Chinese medicine, but also an acknowledgment and encouragement to my colleagues in this field. I am grateful for Mr. Cheung On Tak's contributions to the international development of Chinese medicine, and for the support of my colleagues, peers, and partners around the world. I also thank the adjudicators for their affirmation of my work. Chinese medicine is my lifelong pursuit, and receiving this award further emphasises the great responsibility I carry. In the future, I will continue to spare no effort in promoting the development and exchange of Chinese medicine worldwide, and tirelessly contribute to the health and well-being of all humanity through Chinese medicine.

獲得張安德中醫藥國際貢獻獎，我深感榮耀。這一殊榮不僅是對我研究和發展中醫藥所作努力的肯定，也是對中醫藥同仁們的認可和鼓勵。感謝張安德先生為中醫藥國際化發展所作的貢獻，感謝我的同事、同行和世界各地合作夥伴的支持，也感謝評委們對我的肯定。中醫藥是我畢生的事業，獲頒此獎讓我更加深知責任的重大。未來我將繼續不遺餘力地推動中醫藥在世界範圍內的發展和交流，為中醫藥貢獻於全人類的健康作出不懈的努力。

”

Academician Liu Liang
劉良院士

劉良院士潛心鑽研，開拓中醫藥治療風濕病新路徑；他裨闔縱橫，為傳統中醫藥走向世界不遺餘力。

提名機構
澳門科技大學

“

It is my great honour to be awarded the "7th Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine" together with Academician Liu Liang. It is the affirmation and encouragement of my years of work in traditional Chinese medicine. In the future, I will continue to lead the team to carry on the essence of traditional Chinese medicine while pursuing innovations in the contribution to the internationalisation of Chinese medicine.

非常榮幸和劉良院士一起獲得第七屆張安德中醫藥國際貢獻獎，這是對我多年從事中醫藥工作的一種肯定和鼓勵。在今後的工作中，我將繼續帶領團隊傳承精華、守正創新，為推動中醫藥走向世界貢獻自己的力量。

”

Professor Xu Anlong
徐安龍教授

徐安龍教授的學術成就、中醫藥創新發展上所取得的成果，以及他在推動中醫藥全球化發展的重大貢獻，已在國際間產生深遠影響力。

提名人

全小林院士，中國中醫科學院廣安門醫院主任
田金洲院士，北京中醫藥大學東直門醫院主任
陳可冀院士，中國科學院院士

Winner of the 7th Award 得獎學人簡介

Academician Liu Liang 劉良院士

Liu Liang, M.D., is an Academician of the Chinese Academy of Engineering, Fellow of the US National Academy of Inventors, member of the Academic Division of the Chinese Academy of Medical Sciences, member of the Academic Division of the China Academy of Chinese Medical Sciences, and former President of the Macau University of Science and Technology.

Academician Liu currently serves as the Chairman of the Academic Committee, First-class Professor, Director of the State Key Laboratory of Chinese Medicine Syndrome at Guangzhou University of Chinese Medicine, and the Chief Scientist of Guangdong Provincial Academy of Traditional Chinese Medicine. He also holds positions as the Consultant and Chair of the expert group for the World Health Organization Traditional Medicine Program, Convener of the first working group of the ISO/TC249 Technical Committee on Traditional Chinese Medicine of the International Organization for Standardization (ISO), Director of the Chinese Society of Immunology's Committee on Traditional Chinese Medicine and Immunology, Vice-President of the World Federation of Chinese Medicine Societies (WFCMS), and Honorary Chairman of the Committee on Traditional Chinese Medicine and Immunology of WFCMS.

As a renowned expert in Chinese medicine rheumatology, Academician Liu is a leading figure in integrating multidisciplinary frontier technologies in Chinese medicine research. He has published 350 research papers in SCI-indexed academic journals and authored/edited 18 publications and textbooks. As the first inventor, he has obtained 52 patents authorised both domestically and internationally. He has received 24 awards and honorary titles, including two second-class National Science and Technology Progress Awards, two first-class Natural Science Awards from the Ministry of Education of China, the first National Innovation Pioneer Award, recognition as a National Young and Middle-aged Expert with Outstanding Contributions, the Shulan Medical Award, Certificates of Merit from the Macao SAR Government, Honorary Citizenship of Zhuhai City, Guangdong Province, and Honorary Citizenship of Huaihua City, Hunan Province.

Academician Liu spearheaded the development of Zhengqing Fengtongning, the world's first rheumatic drug targeting prostaglandin E2 synthase-1, and the only monomolecular Chinese medicine drug included in the National Essential Medicines List, which was widely used across China. He also led his team in the international pioneering development of the titanium dioxide-PGC chip, establishing the world's most sensitive quantitative glycomics analysis technology and innovating new methods for diagnosing rheumatoid arthritis and other rheumatic diseases.

Academician Liu has long been engaged in higher education management and scientific research in the Guangdong-Hong Kong-Macao Greater Bay Area, making significant contributions to the development and advancement of higher education and Chinese medicine science and technology in these three areas, as well as to the globalisation of traditional Chinese medicine.

劉良，醫學博士，中國工程院院士、美國國家發明家科學院院士、中國醫學科學院學部委員、中國中醫藥科學院學部委員、澳門科技大學前校長。

劉院士現任廣州中醫藥大學學術委員會主任委員、一級教授、中醫證候全國重點實驗室主任，廣東省中醫藥科學院首席科學家；兼任世界衛生組織傳統醫學項目顧問和專家組主席、國際標準化組織 (ISO) 中醫藥技術委員會 (ISO/TC249) 第一工作組召集人、中國免疫學會中醫藥免疫分會主任委員、世界中醫藥學會聯合會副主席及中醫藥免疫專業委員會榮譽會長等職。

作為著名中醫風濕病學專家，劉院士是融合多學科前沿技術研究中醫藥的領軍人物。他在 SCI 學術期刊發表 350 篇研究論文，主編／參編出版 18 部著作及教材；以第一發明人獲得 52 項國內外授權專利；獲頒發 24 項各級各類科技獎項和榮譽，包括兩項國家科技進步獎二等獎、兩項國家教育部自然科學獎一等獎、首屆全國創新爭先獎、國家有突出貢獻中青年專家、樹蘭醫學獎、澳門特區政府榮譽獎狀、廣東省珠海市榮譽市民、湖南省懷化市榮譽市民等。劉院士主持研發了國際首個作用於前列腺素 E2 終極合成酶 -1 的風濕病治療藥物—正清風痛寧，是唯一被納入國家基本藥物目錄的治療風濕病中藥單體化合物藥物，在全國廣泛應用。他亦帶領團隊在國際上首創二氧化鈦 -PGC 晶片，建立了迄今世界上最靈敏的定量糖組學分析技術，為診斷類風濕關節炎等風濕病建立了新方法。

劉院士長期致力於粵港澳大灣區的高等教育管理及科學研究，對三地高等教育及中醫藥科技的發展與進步，以及推動中醫藥走向世界作出了重要貢獻。



Research Areas; Major Achievements; Reasons for Nomination
(Chinese version only)
研究範疇、主要成就摘要及提名原因

Winner of the 7th Award 得獎學人簡介

Professor Xu Anlong 徐安龍教授

Professor Xu Anlong obtained his Ph.D. from University of Illinois at Urbana-Champaign (UIUC) in 1992. He then conducted postdoctoral research at the University of California, San Diego in 1992-1994 and joined a San Diego-based Alliance Pharmaceutical Corporation in 1994-1996. After 10 years of study and research work in the US, he joined the Department of Biochemistry of College of Life Sciences, Sun Yat-sen (Zhongshan) University (SYSU), his alma mater, in 1996. He served as the Dean of the College of Life Sciences from 2000 to 2008 and was appointed Vice-President for research and development of SYSU in 2008. Currently, Professor Xu focuses on molecular biology and immunology and has been serving as the President of Beijing University of Chinese Medicine (BUCM) since 2013. He has also held positions as the Director of the State Key Laboratory of Biocontrol of Harmful Organisms and Resource Utilization, as well as the National Engineering Research Center of Marine Biotechnology in the South China Sea.

Professor Xu's research focuses on functional genomics, aiming to understand the origin and evolution of vertebrate immune system and discovering new drugs through basic research. He has presided 17 national-level scientific research projects, including the National Outstanding Youth Science Fund, 973 Program, 863 Program, National Natural Science Foundation of China Key Project, and National Key Research and Development Program of China. He has published over 200 papers in peer-reviewed international journals as the corresponding author, such as *Nature*, *Cell*, *Nat Cell Biol*, *J Hepatol*, *Gut*, *Cell Res*, *Signal Transduct Target Ther*, *Natl Sci Rev*, *Kidney Intl*, *PNAS*, *PLoS Biology*, *EMBO Rep*, *J Biol Chem*, *J Immunol*, as well as has served as the editor-in-chief of two publications and has obtained over 60 invention patents in both China and the US. His contributions have been recognised with several scientific awards, including three first prizes of Guangdong Science and Technology Award/ Natural Science Award (2005, 2008 and 2018), the second prize of the National Natural Science Award (2012), the first prize of Science and Technology Award of Chinese Pharmaceutical Association (2017), and the first prize of Beijing Higher Education Teaching Achievement Award (2021).

Professor Xu has received numerous prestigious awards and recognitions throughout his career, including the National Outstanding Youth Science Fund in 1997, the government special allowance issued by the State Council in 2000, the 6th China Youth Science and Technology Innovation Award in 2003, selected as a national-level candidate for the New Century Millions of Talents Project in 2004, recognised as one of the Ten major scientific and technological progress of China's colleges and Universities in 2010, and selected as a Innovation teams in key areas of the Innovation Talent Promotion Plan by the Ministry of Science and Technology in 2013. In 2014, he was selected as one of the first batch of technological innovation leaders in the National High-Level Personnel of Special Support Program. In 2016, he was selected as one of The Top Ten Medical News Figures in China and

was awarded the Ten Major Advances in the Field of Life Sciences in China. In 2021, he won the 14th C. C. Tan Life Science Award and was selected for the Qi-Huang Scholar Program (Integrated Traditional Chinese and Western Medicine) by the National Administration of Traditional Chinese Medicine.

徐安龍教授，現任北京中醫藥大學校長，曾任有害生物控制與資源利用國家重點實驗室主任、南海海洋生物技術國家工程研究中心主任。

徐教授於 1992 年在美國伊利諾伊大學取得博士學位，1992 至 1994 年在加州大學聖地亞哥分校從事博士後研究，1994 至 1996 年在聖地亞哥的聯合製藥公司工作。1996 年回到母校中山大學任教，2000 至 2008 年任中山大學生命科學學院院長，2008 至 2012 年任中山大學副校長。2013 年至今擔任北京中醫藥大學校長。

徐教授主要研究人體免疫防禦多樣性的起源與演化、功能與機制，以及免疫性疾病的防治，取得了原創性和系統性的研究成果；先後主持 17 項國家級科研項目，包括國家傑出青年科學基金、973 計劃項目、863 計劃項目、國家自然科學基金重點項目、國家重點研發計劃等；以通訊作者身份在 *Nature*、*Cell*、*Nat Cell Biol*、*J Hepatol*、*Gut*、*Cell Res*、*Signal Transduct Target Ther*、*Natl Sci Rev*、*Kidney Int*、*PNAS*、*PLoS Biology*、*EMBO Rep*、*J Biol Chem*、*J Immunol* 等國際學術期刊發表逾 200 篇 SCI 論文；主編兩部著作，以及獲得 60 多項中國和美國發明專利。徐教授曾獲多項科技獎項，包括三項廣東省科學技術獎／自然科學獎一等獎（2005、2008 和 2018 年）、國家自然科學獎二等獎（2012 年）、中國藥學會科學技術獎一等獎（2017 年）、北京市高等教育教學成果獎一等獎（2021 年）等。

徐教授於 1997 年獲頒國家傑出青年科學基金、2000 年獲國務院頒發政府特殊津貼、2003 年獲第六屆中國青年科技創新獎、2004 年獲評選為新世紀百千萬人才工程國家級人選、2010 年獲中國高等學校十大科技進展、2013 年入選科技部創新人才推進計劃重點領域創新團隊、2014 年入選萬人計劃第一批科技創新領軍人才、2016 年入選中國十大醫學新聞人物並獲中國生命科學領域十大進展、2021 年獲第十四屆談家楨生命科學成就獎，以及入選國家中醫藥管理局岐黃學者計劃（中西醫結合）。



Research Areas; Major Achievements; Reasons for Nomination
(Chinese version only)
研究範疇、主要成就摘要及提名原因

Synopsis

講座摘要

Original Studies on The Diagnosis and Treatment of Rheumatic Diseases by Integrating Chinese and Western Medicine 中西醫結合診療風濕病的原創性研究

Academician Liu Liang
劉良院士

Rheumatic diseases represent a common and significant group of chronic illnesses. Statistics indicate that approximately 25% of adults suffer from rheumatic and joint diseases. These diseases are characterised by unclear etiologies, complex pathologies, and persistent, debilitating symptoms. Rheumatoid arthritis, colloquially referred to as "RA", is a classic example of these conditions. In managing RA, two prominent clinical challenges arise: the lack of early diagnosis and precise diagnostic biomarkers, as well as the absence of highly effective, low-toxicity specific drugs. These challenges hinder early diagnosis and treatment, resulting in suboptimal clinical remission rates. Academician Liu and his research team have been devoted to conducting multidisciplinary, innovative research focused on addressing these issues. Their relentless efforts have resulted in numerous groundbreaking achievements in this field, which are outlined below.

1. Tackling the global challenge of low-abundance IgG acidic N-glycans, which plays a significant role in the early and precise diagnosis of rheumatic diseases, Academician Liu and his team pioneered the development of TiO₂-PGC chip technology. This groundbreaking technology significantly improved the sensitivity of IgG N-glycan detection by over a thousand times compared to previous methods, making it the most sensitive quantitative glycomics technology available worldwide. The application of this technology has yielded remarkable outcomes, including the discovery of specific serum biomarkers for molecular diagnosis of rheumatic diseases such as RA, ankylosing spondylitis, and systemic lupus erythematosus, substantially enhancing clinical precision in diagnostics. At the same time, the team unveiled characteristic IgG N-glycan expression profiles in RA patients classified as Cold Syndrome and Dampness Syndrome, according to traditional Chinese medicine body constitution differentiation.
2. Developed the first anti-inflammatory and anti-rheumatic drug, "Zhengqing Fengtongning Prolonged-release Tablets," which targets microsomal prostaglandin E₂ synthase-1 (mPGES-1). This drug has been included in the National Essential Medicines List (NEML) of China and is utilised nationwide. It also bridges the international gap in anti-inflammatory drugs targeting mPGES-1.

3. Introduced novel methodologies, animal models and technical platforms for conducting research in the field of rheumatic diseases and anti-inflammatory immunopharmacology. The world's first rat gut microbiota gene set has been created, enabling the manipulation of gut microbiota for the treatment of RA, and an SD rat adjuvant-induced arthritis model has been developed for the research and development of anti-arthritic drugs. Moreover, new mechanisms underlying the pathogenesis of RA, strategies to overcome drug resistance in RA patients, as well as a new binding site for IKK-beta kinase, have been identified.

This body of work showcases Academician Liu's unwavering dedication to advancing the field of rheumatic disease diagnosis and treatment through innovative and groundbreaking research which integrates Chinese and Western medicine approaches. The research findings have not only enhanced diagnostic accuracy and expanded treatment options, but also paved the way for improved therapies and deeper insights into the pathophysiology of these complex diseases.

風濕病是一種常見的重大慢性病。根據統計，成年人中約有 25% 患有風濕和關節疾病。風濕病的共同特點是發病機制不明，病理複雜，病情纏綿難癒。其中，類風濕關節炎（簡稱「類風關」）便是其典型病種之一。類風關有兩大突出的臨床問題，一是缺乏早期診斷和精準診斷的生物標誌物，二是缺乏高效低毒的藥物，導致早診早治困難，臨床病情緩解率低。劉良院士及其研究團隊聚焦上述問題，開展多學科結合創新性研究，獲得了多項原創性成果。

1. 針對具有風濕病早期診斷和精準診斷意義的低豐度 IgG 酸性 N-糖鏈難以檢測這一世界性難題，研究團隊在國際上首創了 TiO₂-PGC 芯片檢測新技術，對 IgG N-糖鏈的檢測靈敏度比先前的檢測方法提高了逾千倍，成為全球迄今最靈敏的定量糖組學技術。團隊應用該技術時發現了類風關、強直性脊柱炎、系統性紅斑狼瘡等多種風濕病分子診斷的特異性血清生物標誌物，顯著提高了臨床精準診斷水平。同時，團隊還發現了類風關中醫辨證屬寒證和濕證患者的特徵性 IgG N-糖鏈表達譜。
2. 研發首個作用於前列腺素 E₂ 終極合成酶 -1 (m-PGES-1) 的抗炎抗風濕新藥—正清風痛寧緩釋片，成為唯一被納入國家基本藥物目錄的治療風濕病中藥單體化合物藥物，在全國廣泛應用。同時，此藥亦填補了作用於 m-PGES-1 抗炎藥物領域的國際空白。
3. 建立了風濕病及抗炎免疫藥理研究的新方法、新模型和新平台，以及調整腸道微生態治療類風關的新策略；開闢了中醫藥治療的新路徑，包括創建了國際上首個大鼠腸道菌群基因集和 SD 大鼠佐劑性關節炎新模型，發現了類風關的發病和克服耐藥新機制，以及 IKK-beta 激酶的藥物結合新靶位。

上述成果彰顯了劉良院士應用中西醫等多學科結合的創新研究方法，在提高風濕病臨床診療水平作出了重要貢獻，不僅提高風濕病的精準診斷水平，還闡明疾病發生的複雜機理，反映中西醫多學科結合對於提高治療效果，進而改善病患者生活質量的可行性。

Synopsis

講座摘要

Internationalisation of TCM: A Unique Way of Mutual Learning Between Eastern and Western Civilisations 中醫國際化：東西方文明互鑒的獨特之道

Professor Xu Anlong
徐安龍教授

In the aspect of international exchanges, we continuously explore the wisdom of traditional Chinese medicine and enhance cultural confidence. During the 2022 "Dialogue on Traditional Chinese Medicine" diplomatic interview series, I had a conversation with Dusan Bella, Ambassador of Slovakia to China and his wife, stating that, "Traditional Chinese medicine is summarised and developed by our ancestors based on observations of natural environment and patterns of climate changes. It is an oriental wisdom, rooted in the harmony of nature, utilises therapies such as herbal medicine and acupuncture to promote the well-being of the body."

Adhering to this philosophy, the Beijing University of Chinese Medicine (BUCM) has been actively promoting the internationalisation of Chinese medicine and expanding its global influence in recent years. BUCM was one of the earliest institutions to receive foreign students and has trained nearly 20,000 students specialising in Chinese medicine from 94 countries and regions. We have also established cooperative relationships with 118 institutions in 31 countries and regions across the globe.

In 2014, we took the lead in proposing the establishment of overseas Chinese Medicine Centre which integrates medical treatment, education, research, and cultural exchange. On 17 November 2014 in Sydney, Australia, China's President Xi Jinping and the then Australian Prime Minister Tony Abbott witnessed the signing of a memorandum of understanding (MoU) on jointly establishing a Chinese Medicine Centre by BUCM and Western Sydney University (WSU). The Centre is a major outcome from the China-Australia Free Trade Agreement, highlighting the collaboration for promoting traditional Chinese medicine for better health and wellbeing through clinical service, education, scientific research and culture exchange. The Chinese medicine collaboration between BUCM and WSU has lasted for more than a decade and has received substantial support from NICM Health Research Institute, the world-class research institute at WSU. The first meeting of the Governing Council of the Chinese Medicine Centre was held on 26 September 2018, co-chaired by the Vice-Chancellor of WSU and myself. This marks a new stage of development for the Centre after years of work in forging the foundations for collaboration.

Additionally, we have opened Chinese Medicine Centers in Maryland, US, St. Petersburg, Russia and other places, promoting international exchanges and cooperation. We persist the principle of "carrying on the essence of traditional Chinese medicine while pursuing innovations in the field," integrating traditional Chinese medicine and modern medical characteristics with the aid of modern biotechnology and artificial intelligence. In the future, we aim to establish multi-disciplinary Traditional Chinese Medicine International Cooperation Centre, creating a new international image for China's humanities and technology.

對外交流上，我們不斷挖掘中醫智慧，增強文化自信。在 2022 年《對話中醫》之外交官系列訪談節目中，我與斯洛伐克駐華大使杜尚·貝拉及大使夫人交流時提到：「中醫是由我們的祖先基於在自然環境以及四季氣候變化規律中所總結和發展起來的，是立足於天地自然，運用藥物、針灸等療法進行身體調護的東方智慧。」

秉承這個理念，北京中醫藥大學近年來不斷推動中醫藥國際化，擴大其在全球的影響力。我校是最早接收外國留學生的高校，目前已經培養了近兩萬名來自 94 個國家和地區的中醫藥專業人才，並與全球 31 個國家和地區的 118 所機構建立了合作關係。

2014 年，我們在全國率先提出，在海外建設「醫、教、研、文」四位一體的「中醫中心」。2014 年 11 月 17 日，在國家主席習近平與時任澳大利亞總理阿伯特的見證下，北京中醫藥大學與澳大利亞西悉尼大學於澳大利亞悉尼就合作開設中醫中心簽署協議。這個項目是中澳自貿協議的重要組成部分，而該中醫中心已經成為中澳之間中醫藥臨床醫療、教育、科學研究、文化交流等方面合作的典範。我校與西悉尼大學之間的中醫藥合作已經超過十年，並得到西悉尼大學的世界級研究機構 NICM 健康研究所的大力支持。中醫中心的第一次管理委員會會議於 2018 年 9 月 26 日舉行，由西悉尼大學校長和我共同主持。這標誌著經過多年努力為合作奠定基礎後，中醫中心進入了一個新的發展階段。

此外，我們在美國馬里蘭州、俄羅斯聖彼得堡等地均開設了中醫中心，促進了中外交流與合作。我們秉持「傳承精華、守正創新」的思想，以傳統中醫藥關於生命的思維為核心，以現代生物技術和人工智能為引領，整合傳統中醫學與現代醫學特色優勢，建立多學科交叉的「國家中醫國際中心」，在全球推廣發展，打造我國人文科技國際新名片。

School of Chinese Medicine, Hong Kong Baptist University
香港浸會大學中醫藥學院

Jockey Club School of Chinese Medicine Building
7 Baptist University Road, Kowloon Tong, Kowloon, Hong Kong
香港九龍塘浸會大學道七號賽馬會中醫藥學院大樓

☎ (852) 3411 5387

✉ scm@hkbu.edu.hk

Award Webpage | 獎項網頁

<http://scm.hkbu.edu.hk/cm-award>



SCM Website | 學院網頁

<http://scm.hkbu.edu.hk>



LinkedIn

hkbuscm



Instagram

hkbuscm



Facebook

scm.hkbu

